Positive results from the first part of Dicot's phase 1 study
Press release: Uppsala, Sweden, January 23, 2024. Dicot presents positive results from the first part of its phase 1 clinical study showing that LIB-01 has a very good safety profile. There were no serious adverse effects. The results also show that the drug is well absorbed in the body, which puts the company in a strong position for clinical phase 2.The primary objective of Dicot's phase 1 study is to investigate the safety of the potency drug candidate LIB-01 in humans. The study is double-blind and placebo-controlled and consists of two parts: SAD and MAD. The SAD part studies